How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Interventional procedure overview of selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver

    Closed for comments This consultation ended on at   Request commenting lead permission

    References

    1. Ngo L, Elnahla A, Attia AS, et al, (2021). Chemoembolization Versus Radioembolization for Neuroendocrine Liver Metastases: A Meta-analysis Comparing Clinical Outcomes, Ann Surg Oncol, 28, 1950-1958.

    2. Frilling A, Clift AK, Braat AJAT, et al, (2019). Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis, HPB, 21, 773-783.

    3. Egger ME, Armstrong E, Martin RCG, et al, (2020). Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: A multi-institutional analysis, Journal of the American College of Surgeons, 230(4), 363-371

    4. Wong TY, Zhang KS, Ghandi RT, et al, (2022). Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry, BMC Cancer, 22, 224.

    5. Braat AJAT, Kappadath SC, Ahmadzadehfar H, et al, (2019). Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity, Cardiovasc Intervent Radiol, 42, 413–425

    6. Braat AJAT, Bruijnen RCG, van Rooij R, et al, (2020). Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study, The Lancet, 21, 561-570.

    7. Tomozawa Y, Jahangiri Y, Pathak P, et al, (2018). Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases. J Vasc Interv Radiol, 29, 858–865.

    8. Cramer B, Xing M, Kim HS (2017). Prospective Longitudinal Quality of Life Assessment in Patients With Neuroendocrine Tumor Liver Metastases Treated With 90Y Radioembolization, Clinical Nuclear Medicine, 41(12), 493-497.

    9. Grozinsky-Glasberg S, Davar J, Hofland J, et al, (2022). European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease, Journal of Neuroendocrinology, 34, e131456.

    10. Kennedy A, Bester L, Salem R, et al, (2015). Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference, HPB, 17, 29–37.

    11. Pavel M, O'Toole D, Costa F, et al, (2016). ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site, Neuroendocrinology, 103, 172-185.

    Figure 1 Flow chart of study selection